Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Pamela Ksenich"'
Autor:
Matthew M. Cooney, Keith R. McCrae, R. Jeff McPeak, Afshin Dowlati, Pamela Ksenich, Vinit Makar, Pierre Lavertu, Kou Yi Tserng, Beth Overmoyer, Charles L. Hoppel, Percy Ivy, Scot C. Remick, Stephen T. Ingalls
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:295-300
SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the com
Autor:
Afshin, Dowlati, Hillard M, Lazarus, Paul, Hartman, James W, Jacobberger, Cecilia, Whitacre, Stanton L, Gerson, Pamela, Ksenich, Brenda W, Cooper, Phyllis S, Frisa, Megan, Gottlieb, Anthony J, Murgo, Scot C, Remick
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(16 Pt 1)
Bryostatin 1 activates protein kinase C (PKC) with short-term exposure and results in depletion of PKC with prolonged exposure. Preclinical in vitro and in vivo studies demonstrate synergistic activity and increased tumor apoptosis in B-cell malignan
Autor:
Colin L. Sweeney, Karen Lingas, Omer N. Koc, Jane S. Reese, Pamela Ksenich, Stanton L. Gerson
Publikováno v:
Molecular Therapy. 9:S385
We have extensively studied the G156A MGMT mutation which confers O6alkylguanine DNA alkyltransferase (AGT) that is resistant to O6benzylguanine (BG). In a Phase I clinical trial at our institution, BG was shown to inhibit tumor AGT at 120mg/m2 and t